Study for continuing or restarting cancer treatment that worked before
Treatments studied
Part of Cancer clinical trials.
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to sign informed consent (agree to take part).
- You must already be eligible for treatment in the earlier “parent” study.
- You either paused treatment due to a long-lasting response, or you can restart it (“rechallenge”) based on the parent study rules.
- If you can get pregnant or you’re male and sexually active, you must follow the trial’s birth-control instructions.
- You should be receiving clinical benefit in the investigator’s judgment (not stopping because it isn’t helping).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This study lets people who already finished (or can no longer continue) an earlier AstraZeneca cancer treatment study keep receiving durvalumab. It tests whether continuing the same kind of treatment on a regular schedule can help keep your cancer under control.
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
This is a “rollover” study for people who were already taking a Roche (or Genentech) cancer study medicine. It checks whether continuing the same study treatment (when commercial options aren’t available) can keep helping you.
This study continues treatment with tucatinib for people who were already benefiting from it in a previous study. It checks if they are still eligible and willing to keep taking the drug.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.